CidpUSA.org
Home
Diagnosis
Treatment
Pathology
Women Heart attack
Women risk diseases
Women stroke Risk
Services Page
Diet
Women ER delay
Inner Ear Disease
Women Killer Disease
Autoimmune diseases
Natural Makeup
Personality
Hair & Chemicals

Vitamins and cancer

Cancer therapy

Cancer Mycoplasma

Breast self exam

Neuropathy testing

Homocysteine

Colostrum

Carbohydrate supplements

Chemicals Babies

 Pain Disorder

Bulimia

Phylates

Toxic Cosmetics

Limbic encephalitis

Detox Baths

Smoking & disease

Breast Size and disease

  

Multifocal neuropathy

Hair rejuvenation

Fatty acids in diseases

Diabetes

Skin hair nail spa

 Vitiligo

Miracle ITP

Cholesterol drugs & Bleeding

What is autoimmune

Toxic Baby products

cancer survivor

Tomato as a medicine

New Vaccine

Acromegaly page   

Summer Sun Benefits  

Ear Infections 

Toxic Effects of Household Chemicals  

Canola Dangers

Fat lowering Diet

Kamut

Homocysteine Lowering diet

The best lifestyle

Takayasu arteritis

Pandas

 hepatitis

irregular periods

ACV

Coconut oil Benefits

Vitamin E Guide

 Under active thyroid

Iodine deficiency china

Women & Thyroid

.

 

 

.

SpecialGoogleHealth Search
Alternative medical treatments read our e-book 

Nervous System Brain


  • Brain images of healthy people reveal that A-beta plaques are common, even in people who don’t have dementia. And mice that make a lot of A-beta have memory problems, but their neurons don’t die, says Li-Huei Tsai, a neuroscientist at MIT. “The role of A-beta is still very, very controversial,” she says. Some people think elevated levels of the protein may interfere with neuron communication. Others think that small aggregates, rather than large clumps, are toxic to cells.

    Part of the difficulty in deciphering A-beta’s role in Alzheimer’s disease is that no one is sure what the protein’s day job is. That’s true of alpha-synuclein, a protein that forms clumps called Lewy bodies inside brain cells of people with Parkinson’s disease, and of huntingtin, a protein which has been shown to be the causative agent of Huntington’s disease. Alpha-synuclein, A-beta and the prion protein PrP probably aren’t unemployed, but scientists have not yet established their roles.

    On the surface, these proteins, as well as two proteins (TDP-43 and superoxide dismutase or SOD1) involved in ALS, have nothing in common, says Mark Goldberg, director of the Hope Center for Neurological Disorders at Washington University in St. Louis. T

    On the straight and narrow

    Although the precipitating event that leads good proteins down the beta-pleated path isn’t known, Wanker and his colleagues may have developed a way to stop the process, at least in the test tube. In a report published in the June Nature Structural & Molecular Biology, Wanker and his collaborators showed that a small molecule called (—)-epigallocatechin gallate (mercifully shortened to EGCG) can keep A-beta and alpha-synuclein from forming beta sheets. The group had previously shown that the compound could prevent huntingtin from aggregating.

    EGCG latches on to the backbones of the amino acid chains that compose the proteins. With EGCG riding piggyback, the proteins form small clumps. But apparently the proteins never switch to the beta-sheet formation, so the little clumps aren’t toxic to cells in the test tube.

    Wanker doesn’t know whether EGCG, found in green tea, would be an effective therapy for neurodegenerative diseases. The researchers have yet to demonstrate that the compound can dissolve existing aggregates. Also, the experiments used equal parts of the molecule to protein in order to stop the proteins from forming the toxic beta sheets, which may mean that therapies would require massive amounts of the compound to work effectively. It’s also not known how well EGCG gets across the blood-brain barrier. If the molecule doesn’t enter the brain easily, doses of EGCG needed to prevent disease might be too high to be practical.

    Cells may already possess molecules that work in the same way EGCG does, Wanker says. Proteins called chaperones also help keep other proteins loose and ready for action. Some evidence suggests that defects in chaperones may be the blow that sets off brain-wasting diseases. “This mechanism may be more common than we think,” Wanker says.

    Other proteins may act as guardian angels to keep would-be neuron killers on the straight and narrow too. One such guardian may be a protein known as Pin1, which could keep another potential killer that stalks the brains of Alzheimer’s disease patients from turning deadly.

    While spotlights have been trained on A-beta as the most likely killer of neurons in Alzheimer’s disease, Kun Ping Lu of Beth Israel Deaconess Medical Center in Boston thinks scientists may be ignoring a more deadly culprit, a protein called tau.

    Tau is normally a hard-working protein that helps create the internal skeleton of the cell by binding to the cell’s frame-supporting microtubules. If not for tau, the long fibers called axons that connect neurons across the brain would break down, severing communication as surely as cutting a fiber-optic cable to a building would. Dendrites, the neuron’s branchlike projections that receive signals from other neurons, would also disintegrate without tau pinning microtubules in place.

    People who have mutations in the gene that encodes tau develop a disease called frontotemporal dementia. The brains of people with this dementia look much like brains of people with Alzheimer’s disease with one critical difference: Frontotemporal dementia patients don’t have plaques in their brains. But they do have tangles of tau in brain cells, and their neurons are as dead as a person with Alzheimer’s disease.

    That leads Lu to believe that tau may be more directly involved in killing neurons than A-beta. In other words, A-beta may order the hit, but tau pulls the trigger. “If, on top of tangles, you add plaques or increase A-beta, now you have massive neurodegeneration,” Lu says.

    Lu lays out the scenario for brain-cell murder this way: A-beta builds up outside neurons, leading to inflammation in the brain. Inflammation prods enzymes called kinases to tack extra phosphates on to tau inside the cells. This causes tau to walk off the job and hang out in hard tangles with other tau molecules that have more phosphates hanging off them than groupies on a rock star. Hyperphosphorylated tau forms such tight bonds with its cronies, not even boiling it in detergent can untangle it, Lu says. After that, it’s all over for the neuron as its axons and dendrites collapse.

    Normally, tau’s protector, Pin1, keeps it from falling in with hardened tangles. Pin1 actually does double duty, watching over tau and APP, the protein precursor to A-beta. Mutations in the gene for Pin1 have now been linked to late-onset Alzheimer’s disease, but not to early onset forms.

    “As people get older and older, Pin1 levels drop, drop, drop,” Lu says.

    Boosting Pin1 levels may help untangle tau in people at risk of Alzheimer’s disease, slowing the disease’s progression or preventing it altogether. Reporting in the May Journal of Clinical Investigation, Lu and colleagues showed that making more of the protein could help protect against tangle formation in mice. But the new research also shows that too much Pin1 can be a bad thing. When researchers increased Pin1 levels in mice carrying the P301L alteration in tau — found in people with frontotemporal dementia — more brain cells died than did in mice that carry the tau mutation but make normal levels of Pin1.

    The poisoning blame game

    Tau is not the only protein that may be getting away with neuron murder while a more high-profile suspect takes the rap. The antioxidant protein superoxide dismutase had been fingered as the killer of spinal cord neurons in people with ALS. A small subset of those with the disease have mutations in the gene for SOD1 that lead to clumping of the protein and the death of neurons that direct motion.

    But recently scientists learned that nearly everyone with ALS has aggregates of a protein called TDP-43 (for TAR DNA binding protein) in their spinal neurons.

    “If TDP-43 is the major pathway, then SOD1 was misdirecting us,” says Christopher Shaw, a neurologist and neurogeneticist at King’s College London. He estimates that about 1 percent of people with ALS have mutations in the gene for TDP-43. Shaw and his colleagues showed in a report published March 21 in Science that those mutations lead the protein to stick together more readily.

    The life cycle of a neuron might explain its susceptibility to damage, Shaw says. Most neurons last a lifetime. The cells don’t divide after they are born and take their place in the brain. Some new neurons do develop in parts of the brain, but most of the 10 billion to 100 billion neurons are present before birth and last until death. The cells never get a day off and they have no backup or replacement.

    Their long lives may lead neurons to produce proteins differently than other cells. “Maybe brain cells have a just-in-time policy,” Shaw says. “You don’t make a lot of protein and stack it up, so therefore you don’t have the same rigorous protein turnover mechanisms.” In other cells in the body, quality control would quickly recognize a misfolded protein and get rid of it before it could cause mischief. The lack of supervision in neurons could make them more vulnerable to rogue proteins.

    “Theories abound,” Yu says, “but none have been definitively proven.”

     

    Return to main page of Neurone Killer

     

    Go to spinal cord section
  •